An important cause of PAH is liver disease. Up to 5% of patients with cirrhosis (scarring in the liver) or portal hypertension (high pressure in the blood vessels of the liver) can develop PAH. All causes of cirrhosis and portal hypertension can develop PAH. Causes The most common causes of cirrhosis (scarring of the liver that leads to … [Read more...]
Major Drug Developments in PAH July 2020
In a surprising development, Complexa abruptly terminated their phase 2 study in PAH. They seem to have taken a page from Reata’s playbook. The news blindsided the PAH community and is a reminder that the development of a successful medication is a long hard road. The company did not provide much explanation. This is the second … [Read more...]
FAQ’s: Borderline Pulmonary Hypertension, Hand Swelling, Children with PAH, Costs
During the past few months, we have not had quite as much time as usual to address our readers questions. Apologies for that. When I am not caring for pulmonary hypertension patients, I wear a critical care doctor’s hat and have been taking care of a growing number of gravely ill COVID patients. At PulmonaryhypertnesionRN.com we appreciate our readers and hope that you are … [Read more...]
Uptravi (Selexipag) for PAH
Uptravi was approved in 2016 to treat Pulmonary Arterial Hypertension, PAH. We now have more than four years of experience with this medication. There are three broad pathways that PAH medications impact. 3 Pathways PAH Medications Impact The endothelin pathway is overactive in PAH and leads to excessive blood vessel squeezing and … [Read more...]
Exciting New Clinical Trials in PAH
The wheels of progress continue to move forward in PAH research. Two companies in particular are preparing to launch very exciting clinical trials. Gossamer Bio Inhaled Drug Study Gossamer Bio, a biopharmaceutic company is preparing to launch a new phase 2 clinical research trial using an inhaled tyrosine kinase inhibitor. About 10 years … [Read more...]
